Axovant's IPO: Harbinger Of A Biotech Bubble?
This article was originally published in Start Up
Executive Summary
In June, Axovant Sciences Ltd. launched an IPO in which its stock almost doubled on the first day of trading and its valuation approached a frothy $3 billion. And this startling performance was attributed to just one asset – an experimental compound for Alzheimer’s disease.